---
schema_version: "secwatch.filing_event.v1"
accession: "0001824293-24-000078"
form_type: "8-K"
ticker: "GRI"
cik: "0001824293"
company_name: "GRI Bio, Inc."
filed_at: "2024-07-08T23:59:59+00:00"
generated_at: "2026-05-31T23:07:09.780718+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# GRI Bio regains compliance with Nasdaq continued listing standards

## Summary
- Received Nasdaq notice on July 2, 2024 curing equity deficiency under Listing Rule 5550(b).
- Scheduled hearing before Nasdaq Hearings Panel has been canceled.
- Now in compliance with all applicable continued listing standards on Nasdaq Capital Market.
- No financial impact or operational changes disclosed; CEO expresses focus on core business.

## SEC filing metadata
- accession: 0001824293-24-000078
- form_type: 8-K
- ticker: GRI
- cik: 0001824293
- company_name: GRI Bio, Inc.
- filed_at: 2024-07-08T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824293/000182429324000078/0001824293-24-000078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824293/000182429324000078/val-20240702.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001824293-24-000078
- JSON: https://secwatch.observer/filing/0001824293-24-000078.json
- Plain text: https://secwatch.observer/filing/0001824293-24-000078.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.